ABSI

MKT CAP:$592M

Absci Corporation

Market Cap

$592M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.94+$0.33 (+9.00%)

Apr 22, 2026

Company Details

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the...

CEO

Alexander Khan

IPO Date

Jul 22, 2021

Website

www.absci.com

Key Metrics TTM

Revenue

$3M

-38.2% YoY

Net Income

-$115M

EPS (Diluted)

-$0.85

Free Cash Flow

-$94M

Revenue / Share

$0.02

Gross Margin

-1316.1%

Operating Margin

-4479.2%

Net Margin

-4113.7%

FCF Margin

-3358.3%

P/S

211.5x

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 24, 2026

$3M-38.2%EPS -$0.84

Q4 2025

Mar 24, 2026

$650.0K-2.3%EPS -$0.20

Q3 2025

Nov 12, 2025

$378.0K-77.8%EPS -$0.20

Q2 2025

Aug 12, 2025

$593.0K-53.3%EPS -$0.24

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$819.0K	-$14M	-$29M
Q2 22	$1M	-$2M	-$29M
Q3 22	$2M	-$1M	-$28M
Q4 22	$2M	-$2M	-$21M
Q1 23	$1M	-$2M	-$24M
Q2 23	$3M	-$9M	-$43M
Q3 23	$744.0K	-$10M	-$23M
Q4 23	$338.0K	-$11M	-$25M
Q1 24	$898.0K	-$11M	-$23M
Q2 24	$1M	-$14M	-$27M
Q3 24	$2M	-$2M	-$29M
Q4 24	$665.0K	-$16M	-$30M
Q1 25	$1M	-$15M	-$28M
Q2 25	$593.0K	-$20M	-$31M
Q3 25	$378.0K	$378.0K	-$30M
Q4 25	$650.0K	-$2M	-$36M

Valuation

Quarter	P/S	P/E
Q1 22	151.0x	—
Q2 22	70.5x	—
Q3 22	48.1x	—
Q4 22	38.7x	—
Q1 23	26.7x	—
Q2 23	16.5x	—
Q3 23	17.2x	—
Q4 23	72.7x	—
Q1 24	104.3x	—
Q2 24	92.1x	—
Q3 24	102.5x	—
Q4 24	66.4x	—
Q1 25	59.9x	—
Q2 25	77.3x	—
Q3 25	134.6x	—
Q4 25	177.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$21M	-$28M
Q2 22	-$23M	-$26M
Q3 22	-$19M	-$24M
Q4 22	-$19M	-$19M
Q1 23	-$20M	-$20M
Q2 23	-$19M	-$19M
Q3 23	-$10M	-$11M
Q4 23	-$15M	-$15M
Q1 24	-$18M	-$18M
Q2 24	-$17M	-$17M
Q3 24	-$21M	-$21M
Q4 24	-$17M	-$17M
Q1 25	-$22M	-$22M
Q2 25	-$17M	-$17M
Q3 25	-$25M	-$26M
Q4 25	-$29M	-$29M

Capital Expenditures

Quarter	CapEx
Q1 22	$7M
Q2 22	$4M
Q3 22	$5M
Q4 22	$560.0K
Q1 23	$280.0K
Q2 23	$256.0K
Q3 23	$307.0K
Q4 23	$17.0K
Q1 24	$0
Q2 24	$333.0K
Q3 24	$48.0K
Q4 24	$23.0K
Q1 25	$25.0K
Q2 25	$223.0K
Q3 25	$962.0K
Q4 25	$103.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-23.0%	+142.6%
Q2 22	+37.6%	+71.6%
Q3 22	+53.9%	+33.8%
Q4 22	+7.2%	-18.3%
Q1 23	+54.9%	-13.1%
Q2 23	+236.0%	+55.1%
Q3 23	-68.6%	-20.7%
Q4 23	-78.3%	+10.7%
Q1 24	-29.2%	-5.3%
Q2 24	-62.3%	-39.6%
Q3 24	+128.6%	+27.2%
Q4 24	+96.7%	+21.4%
Q1 25	+31.3%	+18.5%
Q2 25	-53.3%	+14.3%
Q3 25	-77.8%	-0.2%
Q4 25	-2.3%	+20.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	456.7%
Q2 22	$4M	420.1%
Q3 22	$4M	150.6%
Q4 22	$1M	65.8%
Q1 23	$3M	209.0%
Q2 23	$3M	90.3%
Q3 23	$3M	341.9%
Q4 23	$3M	940.5%
Q1 24	$4M	399.8%
Q2 24	$5M	416.5%
Q3 24	$0	0.0%
Q4 24	$5M	762.1%
Q1 25	$5M	416.7%
Q2 25	$5M	801.5%
Q3 25	$4M	1163.5%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$16M	—
Q2 22	$16M	$11M
Q3 22	$16M	$11M
Q4 22	$11M	$8M
Q1 23	$13M	$10M
Q2 23	$12M	—
Q3 23	$11M	—
Q4 23	$12M	—
Q1 24	$12M	—
Q2 24	$15M	—
Q3 24	$18M	$9M
Q4 24	$18M	—
Q1 25	$16M	—
Q2 25	$20M	—
Q3 25	$19M	—
Q4 25	$25M	$9M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$226M	$0	$226M
Q2 22	$206M	$0	$206M
Q3 22	$107M	$74M	$181M
Q4 22	$60M	$104M	$164M
Q1 23	$11M	$133M	$144M
Q2 23	$61M	$64M	$125M
Q3 23	$70M	$44M	$113M
Q4 23	$72M	$25M	$98M
Q1 24	$59M	$103M	$162M
Q2 24	$43M	$102M	$145M
Q3 24	$38M	$89M	$127M
Q4 24	$41M	$71M	$112M
Q1 25	$47M	$87M	$134M
Q2 25	$38M	$79M	$117M
Q3 25	$9M	$143M	$152M
Q4 25	$20M	$124M	$144M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	90M	+0.6%	-0.1%
Q2 22	91M	+0.4%	+0.3%
Q3 22	91M	+0.5%	+24.3%
Q4 22	91M	+0.2%	+1.7%
Q1 23	91M	+0.2%	+1.3%
Q2 23	92M	+0.4%	+1.3%
Q3 23	92M	+0.4%	+1.2%
Q4 23	93M	+0.4%	+1.4%
Q1 24	99M	+7.4%	+8.7%
Q2 24	113M	+13.6%	+23.0%
Q3 24	114M	+0.6%	+23.2%
Q4 24	115M	+1.2%	+24.2%
Q1 25	124M	+8.3%	+25.2%
Q2 25	128M	+2.5%	+13.0%
Q3 25	144M	+12.7%	+26.5%
Q4 25	151M	+4.8%	+31.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$3.9K	212
Q2 22	$4.7K	212
Q3 22	$11.2K	212
Q4 22	$8.1K	193
Q1 23	$6.6K	193
Q2 23	$17.4K	193
Q3 23	$3.9K	193
Q4 23	$2.2K	156
Q1 24	$5.8K	156
Q2 24	$8.1K	156
Q3 24	$10.9K	156
Q4 24	$4.2K	157
Q1 25	$7.5K	157
Q2 25	$3.8K	157
Q3 25	$2.4K	157
Q4 25	$4.6K	140

Revenue / Employee